Changes in the expression of endothelial monocyte‑activating polypeptide II in the rat hippocampus following status epilepticus

Li,Chun; Ma,Weining; Zhao,Yajuan; Wang,Hua

doi:10.3892/ijmm.2020.4808

Changes in the expression of endothelial monocyte‑activating polypeptide II in the rat hippocampus following status epilepticus

Authors:
- Chun Li
- Weining Ma
- Yajuan Zhao
- Hua Wang
View Affiliations

Affiliations: Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China, Department of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110022, P.R. China
Published online on: December 3, 2020 https://doi.org/10.3892/ijmm.2020.4808
Pages: 699-707
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endothelial monocyte‑activating polypeptide II (EMAP II) is a sensitive marker of neurotoxic injury, the expression of which increases significantly under conditions of stress, such as hypoxia or apoptosis. Studies have confirmed the extensive apoptosis of nerve cells in the brain following status epilepticus (SE), and the occurrence of SE can confer a hypoxic state on cells. The purpose of the present study was to observe the changes in the expression of EMAP II, and in the numbers and tight junction protein levels of microvascular endothelial cells in the hippocampus of rats with pilocarpine‑induced SE. The protein expression levels of EMAP II, CD31, zonula occludens 1 (ZO‑1) and occludin in the hippocampus were determined by immunofluorescence and western blot analyses. It was found that almost 75.6% of the rats in the SE group developed Racine stage IV‑V seizures at approximately 44.7±18.8 min after the pilocarpine administration, and the 24‑h mortality rate was almost 10.4%. The weight of the rats in the SE group was significantly decreased within 24 h following SE. Immunofluorescence staining revealed a low EMAP II expression in the hippocampus of the rats in the control group; however, the numbers of EMAP II‑positive cells were significantly increased in the SE group from 2 h to 21 days. The trend of EMAP II protein expression was consistent with that obtained with immunofluorescence staining. The numbers of CD31‑positive microvascular endothelial cells were significantly increased from 24 h to 21 days compared with the levels in the control group. The protein expression of ZO‑1 and occludin was most significantly decreased in the SE group. On the whole, the present study demonstrated that the expression of EMAP II in the rat hippocampus was upregulated in the SE model, which may promote angiogenesis and alter the TJ integrity of brain microvascular endothelial cells, with an increased number of CD31‑positive microvascular endothelial cells and a decreased expression of ZO‑1 and occludin.

View Figures

View References

1	Thurman DJ, Begley CE, Carpio A, Helmers S, Hesdorffer DC, Mu J, Touré K, Parko KL and Newton CR: The primary prevention of epilepsy: A report of the prevention task force of the international league against epilepsy. Epilepsia. 59:905–914. 2018. View Article : Google Scholar : PubMed/NCBI
2	Fiest KM, Sauro KM, Wiebe S, Patten SB, Kwon CS, Dykeman J, Pringsheim T, Lorenzetti DL and Jetté N: Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. Neurology. 88:296–303. 2017. View Article : Google Scholar :
3	Bertini G, Bramanti P, Constantin G, Pellitteri M, Radu BM, Radu M and Fabene PF: New players in the neurovascular unit: Insights from experimental and clinical epilepsy. Neurochem Int. 63:652–659. 2013. View Article : Google Scholar : PubMed/NCBI
4	Takemiya T and Yamagata K: Intercellular signaling pathway among Endothelia, astrocytes and neurons in excitatory neuronal damage. Int J Mol Sci. 14:8345–8357. 2013. View Article : Google Scholar : PubMed/NCBI
5	Mogylnytska LA: Endothelial monocyte-activating polypeptide-II: Properties, functions, and pathogenetic significance. Fiziol Zh. 61:102–111. 2015.In Ukrainian. View Article : Google Scholar
6	Kao J, Houck K, Fan Y, Haehnel I, Libutti SK, Kayton ML, Grikscheit T, Chabot J, Nowygrod R, Greenberg S, et al: Characterization of a novel tumor-derived cytokine. Endothelial-monocyte activating polypeptide II. J Biol Chem. 269:25106–25119. 1994.PubMed/NCBI
7	Yuan C, Yan L, Solanki P, Vatner SF, Vatner DE and Schwarz MA: Blockade of EMAP II protects cardiac function after chronic myocardial infarction by inducing angiogenesis. J Mol Cell Cardiol. 79:224–231. 2015. View Article : Google Scholar :
8	Lal CV and Schwarz MA: Vascular mediators in chronic lung disease of infancy: Role of endothelial monocyte activating poly-peptide II (EMAP II). Birth Defects Res A Clin Mol Teratol. 100:180–188. 2014. View Article : Google Scholar : PubMed/NCBI
9	Adly AAM, Ismail EA, Tawfik LM, Ebeid FSE and Hassan AAS: Endothelial monocyte activating polypeptide II in children and adolescents with type 1 diabetes mellitus: Relation to micro-vascular complications. Cytokine. 76:156–162. 2015. View Article : Google Scholar : PubMed/NCBI
10	Li Z, Liu XB, Liu YH, Xue YX, Wang P, Liu LB, Liu J, Yao YL and Ma J: Roles of serine/threonine phosphatases in low-dose endothelial monocyte-activating polypeptide-II-induced opening of blood-tumor barrier. J Mol Neurosci. 57:11–20. 2015. View Article : Google Scholar : PubMed/NCBI
11	Ma J, Meng F, Li S, Liu L, Zhao L, Liu Y, Hu Y, Li Z, Yao Y, Xi Z, et al: Autophagy induction by endothelial monocyte activating polypeptide II contributes to the inhibition of malignant biological behaviors by the combination of EMAP II with rapamycin in human glioblastoma. Front Mol Neurosci. 8:742015. View Article : Google Scholar
12	Schikorski D, Cuvillier-Hot V, Boidin-Wichlacz C, Slomianny C, Salzet M and Tasiemski A: Deciphering the immune function and regulation by a TLR of the cytokine EMAPII in the lesioned central nervous system using a leech model. J Immunol. 183:7119–7128. 2009. View Article : Google Scholar : PubMed/NCBI
13	Zhu X, Liu Y, Yin Y, Shao A, Zhang B, Kim S and Zhou J: MSC p43 required for axonal development in motor neurons. Proc Natl Acad Sci USA. 106:15944–15949. 2009. View Article : Google Scholar : PubMed/NCBI
14	Armstrong L, Biancheri R, Shyr C, Rossi A, Sinclair G, Ross CJ, Tarailo-Graovac M, Wasserman WW and van Karnebeek CD: AIMP1 deficiency presents as a cortical neurodegenerative disease with infantile onset. Neurogenetics. 5:157–159. 2014. View Article : Google Scholar
15	Knies UE, Behrensdorf HA, Mitchell CA, Deutsch U, Risau W, Drexler HC and Clauss M: Regulation of endothelial monocyte-activating polypeptide II release by apoptosis. Proc Natl Acad Sci USA. 95:12322–12327. 1998. View Article : Google Scholar : PubMed/NCBI
16	Barnett G, Jakobsen AM, Tas M, Rice K, Carmichael J and Murray JC: Prostate adenocarcinoma cells release the novel proinflammatory polypeptide EMAP-II in response to stress. Cancer Res. 60:2850–2857. 2000.PubMed/NCBI
17	Murray JC, Barnett G, Tas M, Jakobsen A, Brown J, Powe D and Clelland C: Immunohistochemical analysis of endothelial-monocyte-activating polypeptide-II expression in vivo. Am J Pathol. 157:2045–2053. 2000. View Article : Google Scholar : PubMed/NCBI
18	Clauss M, Voswinckel R, Rajashekhar G, Sigua NL, Fehrenbach H, Rush NI, Schweitzer KS, Yildirim AÖ, Kamocki K, Fisher AJ, et al: Lung endothelial monocyte-activating protein 2 is a mediator of cigarette smoke-induced emphysema in mice. J Clin Invest. 121:2470–2479. 2011. View Article : Google Scholar : PubMed/NCBI
19	Rigau V, Morin M, Rousset MC, de Bock F, Lebrun A, Coubes P, Picot MC, Baldy-Moulinier M, Bockaert J, Crespel A, et al: Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy. Brain. 130:1942–1956. 2007. View Article : Google Scholar : PubMed/NCBI
20	Morin-Brureau M, Lebrun A, Rousset MC, Fagni L, Bockaert J, de Bock F and Lerner-Natoli M: Epileptiform activity induces vascular remodeling and zonula occludens 1 downregulation in organotypic hippocampal cultures: Role of VEGF signaling pathways. J Neurosci. 31:10677–10688. 2011. View Article : Google Scholar : PubMed/NCBI
21	Ingram J, Zhang CF, Cressman JR, Hazra A, Wei Y, Koo YE, Žiburkus J, Kopelman R, Xu J and Schiff SJ: Oxygen and seizure dynamics: I. Experiments J Neurophysiol. 112:205–212. 2014. View Article : Google Scholar
22	Wu Q and Wang H: The spatiotemporal expression changes of CB2R in the hippocampus of rats following pilocarpine-induced status epilepticus. Epilepsy Res. 148:8–16. 2018. View Article : Google Scholar : PubMed/NCBI
23	Curia G, Longo D, Biagini G, Jones RS and Avoli M: The pilocarpine model of temporal lobe epilepsy. J Neurosci Methods. 172:143–157. 2008. View Article : Google Scholar : PubMed/NCBI
24	Glien M, Brandt C, Potschka H, Voigt H, Ebert U and Löscher W: Repeated low-dose treatment of rats with pilocarpine: Low mortality but high proportion of rats developing epilepsy. Epilepsy Res. 46:111–119. 2001. View Article : Google Scholar : PubMed/NCBI
25	Racine RJ, Burnham WM and Gartner JG: First trial motor seizures triggered by amygdaloid stimulation in the rat. Electroencephalogr Clin Neurophysiol. 35:487–494. 1973. View Article : Google Scholar : PubMed/NCBI
26	Paxinos G and Watson C: The Rat Brain in Stereotaxic Coordinates - the New Coronal Set. 5th edition. Academic Press; New York: 2005
27	Li J, Jiang G, Chen Y, Chen L, Li Z, Wang Z and Wang X: Altered expression of hypoxia-Inducible factor-1α participates in the epileptogenesis in animal models. Synapse. 68:402–409. 2014. View Article : Google Scholar : PubMed/NCBI
28	Ndode-Ekane XE, Hayward N, Gröhn O and Pitkänen A: Vascular changes in epilepsy: Functional consequences and association with network plasticity in pilocarpine-induced experimental epilepsy. Neuroscience. 166:312–332. 2010. View Article : Google Scholar
29	Friedman A and Heinemann U: Role of blood-brain barrier dysfunction in epileptogenesis. Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th edition. Noebels JL, Avoli M, Rogawski MA, Olsen RW and Delgado-Escueta AV: National Center for Biotechnology Information (US); Bethesda, MD, USA: pp. 1–12. 2012
30	Castañeda-Cabral JL, Colunga-Durán A, Ureña-Guerrero ME, Beas-Zárate C, Nuñez-Lumbreras MLA, Orozco-Suárez S, Alonso-Vanegas M, Guevara-Guzmán R, Deli MA, Valle-Dorado MG, et al: Expression of VEGF- and tight junction-related proteins in the neocortical microvasculature of patients with drug-resistant temporal lobe epilepsy. Microvasc Res. 132:1040592020. View Article : Google Scholar : PubMed/NCBI
31	Kim JY, Ko AR, Hyun HW and Kang TC: ETB receptor-mediated MMP-9 activation induces vasogenic edema via ZO-1 protein degradation following status epilepticus. Neuroscience. 304:355–367. 2015. View Article : Google Scholar : PubMed/NCBI
32	Li Z, Liu YH, Xue YX, Xie H and Liu LB: Role of ATP synthase alpha subunit in low-dose endothelial monocyte-activating poly-peptide-II-induced opening of the blood-tumor barrier. J Neurol Sci. 300:52–58. 2011. View Article : Google Scholar
33	Liao YL, Zhang ZY, Liu JW, Schluesener HJ, Zhang ZR and Wu YZ: Lesional expression of EMAPII in macro-phages/microglia following cerebral ischemia in rats. Int J Neurosci. 121:58–64. 2011. View Article : Google Scholar
34	Brabeck C, Michetti F, Geloso MC, Corvino V, Goezalan F, Meyermann R and Schluesener HJ: Expression of EMAP-II by activated monocytes/microglial cells in different regions of the rat hippocampus after trimethyltin-induced brain damage. Exp Neuro. 177:241–246. 2002. View Article : Google Scholar
35	Li Z, Liu YH, Liu XB, Xue YX, Wang P and Liu LB: Low-dose endothelial monocyte-activating polypeptide-II increases permeability of blood-tumor barrier via a PKC-ζ/PP2A-dependent signaling mechanism. Exp Cell Res. 331:257–266. 2015. View Article : Google Scholar : PubMed/NCBI
36	Li Z, Liu YH, Xue YX, Liu LB and Xie H: Mechanisms for endothelial monocyte-activating polypeptide-II-induced opening of the blood-tumor barrier. J Mol Neurosci. 47:408–417. 2012. View Article : Google Scholar
37	Xie H, Xue YX, Liu LB, Liu YH and Wang P: Role of RhoA/ROCK signaling in endothelial-monocyte-activating polypeptide II opening of the blood-tumor barrier: Role of RhoA/ROCK signaling in EMAP II opening of the BTB. J Mol Neurosci. 46:666–676. 2012. View Article : Google Scholar
38	Park SG, Kang YS, Ahn YH, Lee SH, Kim KR, Kim KW, Koh GY, Ko YG and Kim S: Dose-dependent biphasic activity of tRNA synthetase-associating factor, p43, in angiogenesis. J Biol Chem. 277:45243–45248. 2002. View Article : Google Scholar : PubMed/NCBI
39	Schwarz RE, Awasthi N, Konduri S, Caldwell L, Cafasso D and Schwarz MA: Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation. Cancer Biol Ther. 9:632–639. 2010. View Article : Google Scholar : PubMed/NCBI
40	Awasthi N, Schwarz MA, Verma V, Cappiello C and Schwarz RE: Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling. Lab Invest. 89:38–46. 2009. View Article : Google Scholar